| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.31 | 2e-10 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.23 | 3e-09 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.25 | 5e-07 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.27 | 2e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.22 | 2e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.27 | 4e-05 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.22 | 0.0001 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.31 | 0.0002 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |